

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OPTISCAN IMAGING LIMITED
ABN	81 077 771 987

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Darren Lurie
Date of last notice	21 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	LDL Nominees Pty Ltd <LL & DL Family Trust>
Date of change	12 December 2019
No. of securities held prior to change	Indirect 1,100,000 Performance Rights 2,000,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2019 and expiring 31 May 2022 2,000,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 30 November 2019 and expiring 30 November 2022 2,000,000 Unlisted Options, exercisable at \$0.065, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2020 and expiring 31 May 2023 2,000,000 Unlisted Options, exercisable at \$0.08, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.10 after 30 November 2020 and expiring 30 November 2023

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	1. Fully Paid Ordinary shares 2. Performance Rights
Number acquired	1. 1,100,000 Fully Paid Ordinary Shares 2. 625,000 Fully Paid Ordinary Shares
Number disposed	1,100,000 unlisted performance rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$41,800 (Deemed issue price of \$0.038 per share) 2. \$25,000 (Issue price of \$0.04 per share)
No. of securities held after change	Indirect 1,725,000 Fully Paid Ordinary Shares 2,000,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2019 and expiring 31 May 2022 2,000,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 30 November 2019 and expiring 30 November 2022 2,000,000 Unlisted Options, exercisable at \$0.065, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2020 and expiring 31 May 2023 2,000,000 Unlisted Options, exercisable at \$0.08, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.10 after 30 November 2020 and expiring 30 November 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Exercise of unlisted performance rights into fully paid ordinary shares. 2. Conversion of Loan provided to the Company into Fully Paid Ordinary Shares following receipt of shareholder approval at the Company's 2019 Annual General Meeting of shareholders.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was this provided?	No

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OPTISCAN IMAGING LIMITED
ABN	81 077 771 987

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Philip James Currie
Date of last notice	6 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficial interest in: Lightstorm Pty Ltd <The Hotspice Trust>
Date of change	12 December 2019
No. of securities held prior to change	<p>Direct</p> <p>660,000 Performance Rights</p> <p>1,200,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2019 and expiring 31 May 2022</p> <p>1,200,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 30 November 2019 and expiring 30 November 2022</p> <p>1,200,000 Unlisted Options, exercisable at \$0.065, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2020 and expiring 31 May 2023</p> <p>1,200,000 Unlisted Options, exercisable at \$0.08, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.10 after 30 November 2020 and expiring 30 November 2023</p> <p>Indirect</p> <p>Dr Philip James Currie & Mr Anne Jennifer Currie <Currie Super Fund A/C> 5,097,500 fully paid ordinary shares</p> <p>Lightstorm Pty Ltd <Hotspice A/C> 10,000,000 fully paid ordinary shares</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	1. Fully Paid Ordinary shares 2. Performance Rights
Number acquired	1. 660,000 Fully Paid Ordinary Shares 2. 2,500,000 Fully Paid Ordinary Shares
Number disposed	660,000 unlisted performance rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$25,080 (Deemed issue price of \$0.038 per share) 2. \$100,000 (Issue price of \$0.04 per share)
No. of securities held after change	<p>Direct</p> <p>1,200,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2019 and expiring 31 May 2022</p> <p>1,200,000 Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 30 November 2019 and expiring 30 November 2022</p> <p>1,200,000 Unlisted Options, exercisable at \$0.065, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2020 and expiring 31 May 2023</p> <p>1,200,000 Unlisted Options, exercisable at \$0.08, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.10 after 30 November 2020 and expiring 30 November 2023</p> <p>Indirect</p> <p>Dr Philip James Currie & Mr Anne Jennifer Currie <Currie Super Fund A/C> 7,597,500 fully paid ordinary shares</p> <p>Lightstorm Pty Ltd <Hotspice A/C> 10,660,000 fully paid ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1. Exercise of unlisted performance rights into fully paid ordinary shares. 2. Conversion of Loan provided to the Company into Fully Paid Ordinary Shares following receipt of shareholder approval at the Company's 2019 Annual General Meeting of shareholders.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was this provided?	No

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	OPTISCAN IMAGING LIMITED
ABN	81 077 771 987

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Graeme Mutton
Date of last notice	16 September 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Beneficial interest in: <ol style="list-style-type: none"> 1. Semblance Pty Ltd <Graeme Mutton Retire S/Fund> (beneficiary) 2. Semblance Pty Ltd <Graeme Mutton Retire S/F A/C> (beneficiary) 3. Semblance Pty Ltd (deemed control as holder of more than 20% of shares) 4. Mrs Patricia Mutton & Mr Graeme Mutton <PIM Superfund A/C> (Trustee)
Date of change	12 December 2019
No. of securities held prior to change	Direct 2,508,292 Fully Paid Ordinary Shares 180,000 Performance Rights Indirect <ol style="list-style-type: none"> 1. 3,300,000 Fully Paid Ordinary Shares 2. 3,000,000 Fully Paid Ordinary Shares 3. 446,112 Fully Paid Ordinary Shares 4. 100,000 Fully Paid Ordinary Shares
Class	<ol style="list-style-type: none"> 1. Fully Paid Ordinary Shares 2. Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<ol style="list-style-type: none"> 180,000 fully paid ordinary shares 1,875,000 fully paid ordinary shares
Number disposed	180,000 performance rights
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> \$6,840 (Deemed issue price of \$0.038 per share) \$75,000 (Issue price of \$0.04 per share)
No. of securities held after change	<p>Direct</p> <p>4,563,292 Fully Paid Ordinary Shares</p> <p>Indirect</p> <ol style="list-style-type: none"> 3,300,000 Fully Paid Ordinary Shares 3,000,000 Fully Paid Ordinary Shares 446,112 Fully Paid Ordinary Shares 100,000 Fully Paid Ordinary Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> Exercise of unlisted performance rights into fully paid ordinary shares. Conversion of Loan provided to the Company into Fully Paid Ordinary Shares following receipt of shareholder approval at the Company's 2019 Annual General Meeting of shareholders.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	No
If prior written clearance was provided, on what date was this provided?	No

+ See chapter 19 for defined terms.